Mark Cuban Cost Plus Drug Co. has added Starjemza, a biosimilar to Johnson & Johnson’s Stelara (ustekinumab), to its portfolio.
The company, co-founded by billionaire entrepreneur Mark Cuban, is offering two strengths of the biosimilar at $360 per syringe, plus a $55 next-day refrigerated shipping cost. The retail price for the biosimilar is $3,632 at other pharmacies, according to Cost Plus Drugs’ website.
Stelara is approved to treat patients 6 years and older with plaque psoriasis or psoriatic arthritis, as well as adults with Crohn’s disease or ulcerative colitis. The brand-name biologic costs approximately $30,000, while the generic is about $7,200, according to GoodRx.
The biosimilar Starjemza, approved in May, has the same indications.
Read three other updates on Cost Plus Drugs here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
